Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price
News headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive on Thursday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.5819094811708 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com)
- Walt Disney Company (The) (DIS) Raised to Hold at BidaskClub (healthcaremenu.net)
- Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia (finance.yahoo.com)
- Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
- Vanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia – StreetInsider.com (streetinsider.com)
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.00 on Thursday. The firm has a 50-day moving average of $15.67 and a 200 day moving average of $14.56. The company’s market cap is $712.83 million. Vanda Pharmaceuticals has a 52 week low of $11.00 and a 52 week high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.04. The firm had revenue of $37.42 million during the quarter, compared to analyst estimates of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. Equities analysts anticipate that Vanda Pharmaceuticals will post ($0.70) earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on VNDA shares. Oppenheimer Holdings, Inc. started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 target price on the stock. CIBC reiterated an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. Finally, HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research report on Friday, May 26th. They set a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $21.22.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.